Literature DB >> 24239807

Antiviral signaling protein MITA acts as a tumor suppressor in breast cancer by regulating NF-κB induced cell death.

Khyati Bhatelia1, Aru Singh2, Dhanendra Tomar1, Kritarth Singh1, Lakshmi Sripada1, Megha Chagtoo2, Paresh Prajapati1, Rochika Singh1, Madan M Godbole2, Rajesh Singh3.   

Abstract

Emerging evidences suggest that chronic inflammation is one of the major causes of tumorigenesis. The role of inflammation in regulation of breast cancer progression is not well established. Recently Mediator of IRF3 Activation (MITA) protein has been identified that regulates NF-κB and IFN pathways. Role of MITA in the context of inflammation and cancer progression has not been investigated. In the current report, we studied the role of MITA in the regulation of cross talk between cell death and inflammation in breast cancer cells. The expression of MITA was significantly lower on in estrogen receptor (ER) positive breast cancer cells than ER negative cells. Similarly, it was significantly down regulated in tumor tissue as compared to the normal tissue. The overexpression of MITA in MCF-7 and T47D decreases the cell proliferation and increases the cell death by activation of caspases. MITA positively regulates NF-κB transcription factor, which is essential for MITA induced cell death. The activation of NF-κB induces TNF-α production which further sensitizes MITA induced cell death by activation of death receptor pathway through capsase-8. MITA expression decreases the colony forming units and migration ability of MCF-7 cells. Thus, our finding suggests that MITA acts as a tumor suppressor which is down regulated during tumorigenesis providing survival advantage to tumor cell.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; MITA; NF-κB; Tumor suppressor gene

Mesh:

Substances:

Year:  2013        PMID: 24239807     DOI: 10.1016/j.bbadis.2013.11.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Targeting of PP2Cδ By a Small Molecule C23 Inhibits High Glucose-Induced Breast Cancer Progression In Vivo.

Authors:  Ke Wu; Xiaoting Yu; Zhimin Huang; Donghui Zhu; Xianghua Yi; Ying-Li Wu; Qiongyu Hao; Kevin T Kemp; Yahya Elshimali; Roshni Iyer; Kytai Truong Nguyen; Shilong Zheng; Guanglin Chen; Qiao-Hong Chen; Guangdi Wang; Jaydutt V Vadgama; Yong Wu
Journal:  Antioxid Redox Signal       Date:  2018-07-13       Impact factor: 7.468

Review 2.  STING Signaling in Cancer Cells: Important or Not?

Authors:  Olga Sokolowska; Dominika Nowis
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2017-07-26       Impact factor: 4.291

3.  CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer.

Authors:  Robert Cornelison; Kuntal Biswas; Danielle C Llaneza; Alexandra R Harris; Nisha G Sosale; Matthew J Lazzara; Charles N Landen
Journal:  Cancers (Basel)       Date:  2021-10-09       Impact factor: 6.575

4.  STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.

Authors:  Yanyan Da; Yuxia Liu; Yuan Hu; Wenzeng Liu; Junpeng Ma; Nan Lu; Chengsheng Zhang; Cai Zhang
Journal:  Oncoimmunology       Date:  2022-03-21       Impact factor: 8.110

5.  Application of Gaussia luciferase in bicistronic and non-conventional secretion reporter constructs.

Authors:  Christin Luft; Jamie Freeman; David Elliott; Nadia Al-Tamimi; Janos Kriston-Vizi; Jacob Heintze; Ida Lindenschmidt; Brian Seed; Robin Ketteler
Journal:  BMC Biochem       Date:  2014-07-09       Impact factor: 4.059

Review 6.  Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy.

Authors:  Juyan Zheng; Junluan Mo; Tao Zhu; Wei Zhuo; Yueneng Yi; Shuo Hu; Jiye Yin; Wei Zhang; Honghao Zhou; Zhaoqian Liu
Journal:  Mol Cancer       Date:  2020-08-27       Impact factor: 27.401

7.  Comprehensive analysis of FKBP4/NR3C1/TMEM173 signaling pathway in triple-negative breast cancer cell and dendritic cell among tumor microenvironment.

Authors:  Hanchu Xiong; Zihan Chen; Baihua Lin; Weijun Chen; Qiang Li; Yucheng Li; Min Fang; Ying Wang; Haibo Zhang; Yanwei Lu; Aihong Bi; Shuqiang Wu; Yongshi Jia; Xiao Wang
Journal:  Mol Ther Oncolytics       Date:  2022-01-04       Impact factor: 7.200

8.  Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer.

Authors:  Arjan Kol; Joyce M Lubbers; Anouk L J Terwindt; Hagma H Workel; Annechien Plat; G Bea A Wisman; Joost Bart; Hans W Nijman; Marco De Bruyn
Journal:  Oncoimmunology       Date:  2021-06-12       Impact factor: 8.110

9.  Association of homozygous variants of STING1 with outcome in human cervical cancer.

Authors:  Joyce M Lubbers; Bart Koopman; Jessica M de Klerk-Sluis; Nienke van Rooij; Annechien Plat; Harry Pijper; Timco Koopman; Bettien M van Hemel; Harry Hollema; Bea Wisman; Hans W Nijman; Marco de Bruyn
Journal:  Cancer Sci       Date:  2020-11-20       Impact factor: 6.518

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.